Legal & IP
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Legal Issues
High price of Mallinckrodt’s H.P. Acthar Gel is important factor in conclusion, HHS Office of Inspector General advisory opinion notes.
Court orders agency to provide 48 hours' notice before issuing decision that would allow any manufacturer other than Teva to launch a generic.
Boehringer stands out in its decision to litigate rather than settle, and the firm has obtained AbbVie's settlement agreements with other biosimilar makers.
Firms contend that IPR should not apply to patents filed before America Invents Act was enacted, objecting to IPR decisions invalidating Humira, Avastin and Herceptin patents.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.